CDKL5 deficiency-related neurodevelopmental disorders: a multi-center cohort study in Italy
- PMID: 38874638
- PMCID: PMC11319418
- DOI: 10.1007/s00415-024-12421-1
CDKL5 deficiency-related neurodevelopmental disorders: a multi-center cohort study in Italy
Erratum in
-
Correction to: CDKL5 deficiency-related neurodevelopmental disorders: a multi-center cohort study in Italy.J Neurol. 2024 Dec;271(12):7648-7649. doi: 10.1007/s00415-024-12653-1. J Neurol. 2024. PMID: 39476250 Free PMC article. No abstract available.
Abstract
CDKL5 deficiency disorder (CDD) is a complex clinical condition resulting from non-functional or absent CDKL5 protein, a serine-threonine kinase pivotal for neural maturation and synaptogenesis. The disorder manifests primarily as developmental epileptic encephalopathy, with associated neurological phenotypes, such as hypotonia, movement disorders, visual impairment, and gastrointestinal issues. Its prevalence is estimated at 1 in 40,000-60,000 live births, and it is more prevalent in females due to the lethality of germline mutations in males during fetal development. This Italian multi-center observational study focused on 34 patients with CDKL5-related epileptic encephalopathy, aiming to enhance the understanding of the clinical and molecular aspects of CDD. The study, conducted across 14 pediatric neurology tertiary care centers in Italy, covered various aspects, including phenotypic presentations, seizure types, EEG patterns, treatments, neuroimaging findings, severity of psychomotor delay, and variant-phenotype correlations. The results highlighted the heterogeneity of seizure patterns, with hypermotor-tonic-spasms sequence seizures (HTSS) noted in 17.6% of patients. The study revealed a lack of clear genotype-phenotype correlation within the cohort. The presence of HTSS or HTSS-like at onset resulted a negative prognostic factor for the presence of daily seizures at long-term follow-up in CDD patients. Despite extensive polypharmacotherapy, including medications such as valproic acid, clobazam, cannabidiol, and others, sustained seizure freedom proved elusive, affirming the inherent drug-resistant nature of CDD. The findings underscored the need for further research to explore response rates to different treatments and the potential role of non-pharmacological interventions in managing this challenging disorder.
Keywords: Antiseizure medication; CDKL5 deficiency disorder; Cortical blindness; EEG; Hypermotor-tonic-spasms sequence seizures.
© 2024. The Author(s).
Conflict of interest statement
The authors have no conflict of interest to declare.
References
-
- Fehr S, Wong K, Chin R et al (2016) Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder. Neurology 87:2206–2213 - PubMed
-
- Fehr S, Downs J, Ho G et al (2016) Functional abilities in children and adults with the CDKL5 disorder. Am J Med Genet A 170:2860–2869 - PubMed
-
- Hagebeuk EE, Marcelis CL, Alders M, Kaspers A, deWeerd AW (2015) Two siblings with a CDKL5 mutation: genotype and phenotype evaluation. J Child Neurol 30:1515–1519 - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources